EUVIMEDEUVIMED entdecken
Open Access · CC BY-NC 4.0

Infectious Morbidity During Pediatric Acute Myeloid Leukemia Chemotherapy in a High‐Income Country: A 15‐Year Population‐Based Overview

Emily R Schwartz iD, Kim Klein, Birgit I Lissenberg-Witte, Tom F W Wolfs, Valérie de Haas iD, Bianca Goemans, Natasja Dors, Marry M van den Heuvel-Eibrink, Rutger R G Knops, Wim J E Tissing, Birgitta A Versluys, C Michel Zwaan und 2 weitere

Pediatric Blood & Cancer · 2025

DOI: 10.1002/pbc.31819 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Pediatric Blood & Cancer, 2025. Verfasst von Emily R Schwartz und 13 weiteren Autor:innen. Beteiligte Einrichtung: Pediatric Oncology, Emma Children's Hospital, Amsterdam UMC, Vrije Universiteit Amsterdam, Cancer Center Amsterdam, Amsterdam, The Netherlands. Hauptthemen laut MEDLINE: Leukemia, Myeloid, Acute, Antineoplastic Combined Chemotherapy Protocols, Invasive Fungal Infections. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 43 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Introduction

Infection causes significant morbidity and mortality in pediatric acute myeloid leukemia (pAML). This study describes the incidence and risk factors of bloodstream infection (BSI) and invasive fungal infection (IFI) in pAML.

Methods

A retrospective chart review was performed of patients treated according to the ANLL‐97/AML‐12 ( N = 116), AML‐15 ( N = 60), or DB AML‐01 ( N = 67) protocols between 1998 and 2014. Cumulative incidence was analyzed for infectious outcomes (any BSI, viridans group streptococci [VGS‐BSI], Gram‐negative rod [GNR‐BSI], IFI). Risk factors were analyzed in multivariable models. Recurrent event analyses were performed to evaluate whether previous infection(s) were related to subsequent infection.

Results

The cumulative incidence of any BSI was 78%, VGS‐BSI 35%, GNR‐BSI 15%, and IFI 11% through Day 150. Incidence of GNR‐BSI decreased over time; AML‐15 hazard ratio ([HR] 0.37, 95% confidence interval [CI]: 0.14–0.98, p = 0.045) and DB AML‐01 (HR 0.42, 95% CI: 0.18–0.97, p = 0.042) compared to ANLL‐97/AML‐12. White blood cell counts ≥20 × 10 9 /L at diagnosis and older age were associated with lower infection risk. Recurrent event analyses showed a higher risk of subsequent BSI for patients who had two or more prior BSIs.

Conclusion

Despite efforts to improve supportive care in pAML, only GNR‐BSI cumulative incidence declined over time. Future studies should continue working toward decreasing the incidence of infection while maintaining treatment efficacy.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Leukemia, Myeloid, AcuteAntineoplastic Combined Chemotherapy ProtocolsInvasive Fungal InfectionsHumansMaleRetrospective StudiesFemaleChildAdolescentChild, PreschoolIncidenceInfantRisk FactorsFollow-Up StudiesPrognosis

Stichwörter der Autor:innen

childreninfectionleukemiamorbidityoncology

Autor:innen und Institutionen

  • Pediatric Oncology, Emma Children's Hospital, Amsterdam UMC, Vrije Universiteit Amsterdam, Cancer Center Amsterdam, Amsterdam, The Netherlands.
  • University Medical Center Utrecht/Wilhelmina Children's Hospital, Utrecht, The Netherlands.
  • Princess Máxima Center for Pediatric Oncology, Utrecht, The Netherlands.
  • Epidemiology and Data Science, Amsterdam UMC, Vrije Universiteit Amsterdam, Amsterdam, The Netherlands.
  • Radboud University Medical Center, Nijmegen, The Netherlands.
  • University Medical Center Groningen, Groningen, The Netherlands.

ORCID-Profile: Emily R Schwartz, Valérie de Haas

Zitieren

APA

Schwartz, E. R., Klein, K., Lissenberg-Witte, B. I., Wolfs, T. F. W., de Haas, V., Goemans, B., Dors, N., van den Heuvel-Eibrink, M. M., Knops, R. R. G., Tissing, W. J. E., Versluys, B. A., Zwaan, C. M., van Litsenburg, R. R. L., & Kaspers, G. J. L. (2025). Infectious Morbidity During Pediatric Acute Myeloid Leukemia Chemotherapy in a High‐Income Country: A 15‐Year Population‐Based Overview. Pediatric Blood & Cancer. https://doi.org/10.1002/pbc.31819

Vancouver

Schwartz ER, Klein K, Lissenberg-Witte BI, Wolfs TFW, de Haas V, Goemans B, et al. Infectious Morbidity During Pediatric Acute Myeloid Leukemia Chemotherapy in a High‐Income Country: A 15‐Year Population‐Based Overview. Pediatric Blood & Cancer. 2025. doi:10.1002/pbc.31819

BibTeX
@article{Schwartz2025,
  author = {Schwartz, Emily R and Klein, Kim and Lissenberg-Witte, Birgit I and Wolfs, Tom F W and de Haas, Valérie and Goemans, Bianca and Dors, Natasja and van den Heuvel-Eibrink, Marry M and Knops, Rutger R G and Tissing, Wim J E and Versluys, Birgitta A and Zwaan, C Michel and van Litsenburg, Raphaële R L and Kaspers, Gertjan J L},
  title = {Infectious Morbidity During Pediatric Acute Myeloid Leukemia Chemotherapy in a High‐Income Country: A 15‐Year Population‐Based Overview},
  journal = {Pediatric Blood & Cancer},
  year = {2025},
  doi = {10.1002/pbc.31819}
}
Kostenlos starten →